GDRX

Over the past six months, GoodRx's stock price has experienced a significant decline of approximately 55%. In Q1 2026, GoodRx reported revenue of $194 million, surpassing forecasts but representing a 4.4% year-over-year decrease. The company raised its full-year 2026 revenue guidance due to stronger performance in its Pharma Direct segment. Pharma Direct revenue increased significantly, while prescription transactions revenue decreased. Monthly active consumers remained flat. GoodRx expanded its offerings to include access to GLP-1 drugs and announced collaborations with Viatris and Pfizer. Director Ian T. Clark resigned, and Chief Accounting Officer Romin Nabiey also departed.